The FDA Expands Collaboration With CN Bio to Investigate Lung-on-a-chip Model for Inhaled Drug Evaluation Applications Follows success of initial project demonstrating the advanced performance of the Company's liver-on-a-chip platform CN Bio, a leading developer of single- and multi-organ-on-chip microphysiological systems (MPS) that improve the accuracy and efficiency of drug discovery, today announced the U.S. Food and Drug Administration (FDA) has extended their research collaboration, for a further three years. The scope of the research carried out with the FDA's Center for Drug Evaluati...